一个与多巴胺3受体结合的比托普激动剂揭示了一个选择性位点
Sandra Arroyo-Urea1,2, Antonina L Nazarova3,4, Ángela Carrión-Antolí1,2
1Institute for Biocomputation and Physics of Complex Systems (BIFI), University of Zaragoza, Zaragoza, Spain.
Nature communications
|September 5, 2024
概括
开发用于氨基基G蛋白结合受体 (GPCRs) 的亚型选择性药物具有挑战性. 比托皮带显示出有前途,这项研究揭示了一个新的结合区域,用于设计针对多巴胺D3受体 (hD3R) 的选择性药物.
科学领域:
- 药理学 药理学是指药理学的学科.
- 结构生物学 结构生物学
- 神经科学是一个神经科学.
背景情况:
- 氨基基基G蛋白结合受体 (GPCR) 是关键的药物标,但由于保留的结合部位,难以实现亚型选择性.
- 比托普性配体,结合了奥托斯特和艾洛斯特元素,提供了一种提高GPCR选择性和减少副作用的策略.
- 关于比托普连接体结合的结构数据有限,阻碍了合理的药物设计.
研究的目的:
- 为了确定针对氨基基GPCRs的比托普配体的亚型选择性的结构基础.
- 为了阐明一种新型比托普激动剂 (FOB02-04A) 在人类多巴胺D3受体 (hD3R) 的结合模式.
- 确定新的区域和开发亚型选择性药物的战略.
主要方法:
- 电子显微镜 (cryo-EM) 用于确定hD3R:GαOβγ复合物的结构.
- 结构,功能和计算分析,以了解连接体结合和受体激活.
- 分析TM2-ECL1-TM1区域在选择性中的作用.
主要成果:
- 确定了hD3R:GαOβγ复合体与选择性比托普激动剂FOB02-04A的冷-EM结构.
- 对FOB02-04A的结合模式的洞察揭示了TM2-ECL1-TM1区域的重要性.
- 这一区域涉及TM1的N终端排序,作为亚型选择性的关键决定因素.
结论:
- TM2-ECL1-TM1区域代表了一个新且未被充分利用的区域,用于氨基基GPCRs的药物开发.
- 这一发现扩大了GPCR中已知的全结合口袋.
- 该研究为设计针对氨基基GPCRs (包括hD3R) 的新型,亚型选择性药物的结构性基础,包括hd3R.
相关概念视频
Drug-Receptor Interaction: Agonist
2.4K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
2.4K
Dose-Response Relationship: Selectivity and Specificity
6.5K
Drugs exert their therapeutic effects by interacting with receptors, enzymes, or ion channels that are present throughout the human body. The strength and duration of the interaction between a drug and its target receptor are characterized by the selectivity and specificity of the drug. Selectivity refers to a drug's strong preference for its intended target over other targets. For instance, isoprenaline, a non-selective β-adrenergic agonist, interacts with both β1- and...
6.5K
Adrenergic Agonists: Chemistry and Structure-Activity Relationship
2.6K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
2.6K
Drug-Receptor Interactions
5.1K
Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
5.1K
Opioid Receptors: Overview
589
Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2,...
589
Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
903
Cholinergic agonists or cholinomimetics mimic the action of acetylcholine to stimulate the parasympathetic nervous system. They are categorized into direct-acting and indirect-acting agents. The direct-acting cholinergic drugs induce the parasympathetic response by directly binding to the muscarinic or nicotine receptors. In comparison, the indirect-acting cholinergic drugs prevent acetylcholine hydrolysis, indirectly contributing to the extended parasympathetic response.
The direct-acting...
The direct-acting...
903


